Why we measure it

CEA is a protein normally present at low levels in adults. Its main established use is in oncology, where a rising CEA after colorectal cancer surgery is a recognised early sign of recurrence. In an annual protocol for people without known illness, CEA serves a different purpose: building a personal baseline so that a sustained trend stands out. A CEA that rises from 1.2 to 2.1 to 3.8 ng/mL over three annual draws — each individually 'normal' — tells a story no single reading could. Research gives more weight to raised levels across several gastrointestinal markers at once (CEA, CA 19-9, AFP). CEA is not a substitute for colorectal cancer screening, and it is not diagnostic on its own — smoking, liver conditions, and inflammatory bowel disease also raise it.

Why every 12 months

Annual testing is the appropriate cadence for CEA in a health surveillance context. More frequent testing raises false-positive anxiety without improving sensitivity for clinically significant disease; less frequent testing reduces the trend data needed for meaningful interpretation. A sustained CEA above the reference range on two consecutive annual draws — particularly in the absence of known benign causes — is, in research, a reason to discuss with a registered medical practitioner.

What movement means

The upper reference limit for CEA is typically 2.5 ng/mL for non-smokers and approximately 5.0 ng/mL for smokers, though laboratory-specific ranges vary. The trend and the rate of rise — not the absolute level — are the most clinically informative features in a surveillance context.

This page summarises published research for general education. It is not medical advice and does not interpret individual results. Discuss your results with a registered medical practitioner.

In the protocol